Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma
Post date: Jul 27, 2015 2:58:12 PM
Patients were randomised to different sequences of olodaterol with 2-week washout, either as a total daily dose of 5 μg (5 μg QD [AM] or 2.5 μg BID) or placebo, or 10 μg (10 μg QD [AM] or 5 μg BID) or placebo. All doses and dose frequencies provided adequate 24-h bronchodilation superior to placebo. Further studies are necessary to confirm the optimum dosing regimen in asthma.